Trial Profile
A Phase II, Randomized, Active Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2021
Price :
$35
*
At a glance
- Drugs Etravirine (Primary) ; HIV protease inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Janssen R&D Ireland
- 06 Oct 2009 Actual end date (Jun 2006) added as reported by ClinicalTrials.gov.
- 01 Nov 2008 Results published in HIV Medicine, according to 1129114.
- 09 Apr 2008 Status changed from in progress to completed, according to ClinicalTrials.gov.